Scandinavian Real Heart

“We are very pleased to share this positive update. Results from the implantation test show that Realheart® TAH achieved the targeted cardiac output, resulting in adequate perfusion of the body with low mechanical stress and damage to red blood cells” says Ina Laura Perkins, CEO of Realheart.

Throughout the study the device functioned as intended. At one week the study was terminated as there had been some signs of bleeding which is a common complication of large cardiac surgery.

“A 7-day chronic implantation is a meaningful milestone for our development as this duration affords the assessment of the device performance in an animal that is awake and ambulatory and under various cardiac loads and allows for the elimination of many post-surgical effects”, says CEO Ina Laura Perkins.

The company is currently conducting a preclinical program to evaluate the safety and function of Realheart® TAH prior to conducting clinical studies in heart failure patients. The results from this test will guide further preclinical testing of Realheart® TAH and serve as an integral part of the data set used in dialogue with regulatory agencies.